The scale of the problem is difficult to overstate. The global economic burden of heart failure reached an estimated 284.17 billion dollars in 2021, split almost evenly between direct medical expenses and indirect costs such as lost productivity. Up to 80 percent of patients experience repeated hospital admissions, and the five-year mortality rate hovers near 50 percent. Despite decades of progress in neurohormonal blockade and guideline-directed therapy, outcomes for many patient subgroups, particularly those with preserved ejection fraction, remain disappointingly static. The authors argue that this therapeutic plateau reflects an incomplete understanding of the molecular machinery driving the syndrome.

Cellular senescence offers one of the most compelling explanations for that gap. Senescent cells have permanently exited the cell cycle yet remain metabolically active, and they accumulate steadily in aging and stressed cardiac tissue. Rather than simply idling, these cells adopt what biologists call the senescence-associated secretory phenotype, or SASP, flooding their surroundings with pro-inflammatory cytokines, chemokines, growth factors, and proteases. This chronic inflammatory milieu damages neighboring cells, promotes fibrosis, disrupts mitochondrial function, and triggers secondary senescence in previously healthy cardiac cells, creating a self-perpetuating cycle of tissue deterioration.

The consequences for cardiac function are specific and measurable. Senescent cardiomyocytes suffer mitochondrial damage, impaired contractility, and metabolic dysfunction, all of which reduce cardiac output and produce the fatigue and exercise intolerance characteristic of heart failure. Senescent endothelial cells and the loss of microvasculature compromise coronary blood flow and oxygen delivery, worsening shortness of breath, angina-like discomfort, and fluid retention. Meanwhile, senescence-driven activation of fibroblasts and abnormal extracellular matrix remodeling stiffen the ventricles, a hallmark particularly of heart failure with preserved ejection fraction. Clinical studies have linked senescence markers to worse outcomes in both ischemic and non-ischemic cardiomyopathies.

Enter sirtuin 1, or SIRT1, a NAD+-dependent class III histone deacetylase encoded on chromosome 10. SIRT1 removes acetyl groups from specific histone lysines, including H3K9ac, H3K14ac, and H4K16ac, compacting chromatin and suppressing transcription at targeted loci. It also deacetylates non-histone regulators such as NF-κB, p53, FOXO transcription factors, and PGC-1α, weaving together control of inflammation, stress resistance, DNA repair, and metabolism. Because its enzymatic activity depends directly on intracellular NAD+ levels, SIRT1 functions as a metabolic sensor, translating the cell’s energy state into epigenetic instructions.

Within the cardiovascular system, SIRT1 is expressed most abundantly in endothelial cells, where it supports nitric oxide production, antioxidant defenses, and angiogenesis while inhibiting endothelial senescence and atherosclerotic progression. In cardiomyocytes, moderate SIRT1 activity activates PGC-1α to drive mitochondrial biogenesis and efficient oxidative phosphorylation, deacetylates p53 and FOXO3a to limit apoptosis, and restrains hypertrophic signaling through the AKT-MTOR and NF-κB pathways while boosting AMPK-dependent metabolic reprogramming. Reduced SIRT1 activity, common in aging, diabetes, obesity, and chronic inflammation, dismantles these protections, elevating reactive oxygen and nitrogen species, damaging mitochondrial DNA, and enhancing TGF-β/SMAD-driven fibrosis.

Yet the relationship is strikingly nonlinear. Mouse studies reveal that SIRT1 behaves as a hormetic regulator, beneficial only within a narrow window. Overexpression at 2.5 to 7.5 times normal levels enhances FOXO-dependent antioxidant enzymes such as catalase and preserves contractile function. But at approximately 12.5-fold overexpression, basal oxidative stress rises, apoptosis and hypertrophy increase, and dilated cardiomyopathy develops, accompanied by mitochondrial depletion and disturbed fatty acid metabolism. Supraphysiologic SIRT1 broadens its deacetylation to many targets, repressing fatty acid oxidation programs and impairing mitochondrial respiration. Too little SIRT1 and too much are both harmful; only the optimal range protects.

Perhaps the most provocative finding the review highlights is that senescence actively destroys SIRT1. Under stress-induced premature senescence, the cell-cycle-regulated ubiquitin ligase complex APC/C-Cdh1 tags SIRT1 for proteasomal degradation, while the protein AROS can competitively prevent this loss. This degradation amplifies SASP gene expression, including interleukin-1 and interleukin-6, feeding the inflammatory fire. Cardiac stress compounds the problem: checkpoint kinase 1 normally phosphorylates SIRT1 at threonine 530, shielding it from SMURF2-mediated ubiquitination, and loss of this protection accelerates mitochondrial dysfunction after ischemia-reperfusion injury. Doxorubicin chemotherapy offers another example, inducing the senescence-associated microRNA miR-34a, which directly represses SIRT1 and activates p66Shc signaling, driving cardiomyocyte death and senescence.

These mechanisms carry immediate therapeutic implications. SGLT2 inhibitors such as empagliflozin and dapagliflozin, now cornerstone heart failure drugs, trigger a fasting-mimicry metabolic state that activates the SIRT1, PGC-1α, and FGF21 axis, promoting autophagy and reducing oxidative stress. Conventional neurohormonal therapies, including ACE inhibitors, ARBs, ARNI, and beta blockers, indirectly reduce the oxidative and inflammatory burdens that SIRT1 also counters, suggesting that SIRT1-based interventions could complement standard care. NAD+ boosters such as nicotinamide riboside and nicotinamide mononucleotide, along with caloric restriction and exercise, may restore SIRT1 activity depleted by aging. Senolytic drugs that clear senescent cells and senomorphics that suppress SASP represent parallel strategies that could pair naturally with SIRT1 modulation.

Significant questions remain before these ideas reach the clinic. Researchers still do not know whether SIRT1 decline precedes senescence or results from it, which cardiac compartment initiates the cascade in different heart failure phenotypes, or whether SIRT1 activation might paradoxically sustain dysfunctional senescent cardiomyocytes in late-stage disease. Most evidence derives from rodent and cellular models, no reliable biomarker of cardiac SIRT1 activity exists in humans, and current SIRT1 activators suffer from poor pharmacokinetics. Single-cell and spatial multi-omics mapping of SIRT1 expression, NAD+ levels, and senescence markers across human heart tissue may resolve these uncertainties. What is already clear, the authors conclude, is that the SIRT1-senescence axis is no longer peripheral to cardiology; it is a central driver of heart failure pathogenesis and a promising target for the next generation of therapies.

Subject of Research: The role of sirtuin 1 in linking cellular senescence to heart failure pathogenesis and therapy

Article Title: Sirtuin 1 is a key molecular link between cellular senescence and heart failure

Article References: Krekora, J., Drożdż, J., & Blasiak, J. (2026). Sirtuin 1 is a key molecular link between cellular senescence and heart failure. Frontiers in Molecular Medicine, 6, Article 1818104. https://doi.org/10.3389/fmmed.2026.1818104

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1818104

Keywords: sirtuin 1, cellular senescence, heart failure, SASP, mitochondrial dysfunction, NAD+, senolytics, senomorphics, cardiac aging, endothelial dysfunction, SGLT2 inhibitors, cardiomyocytes

The endothelium, once regarded as a passive lining of blood vessels, is now understood as an active, semi-permeable metabolic and endocrine monolayer that regulates vascular tone, leukocyte trafficking, and permeability. When endothelial cells undergo senescence—an irreversible cell cycle arrest driven by telomere attrition, oxidative stress, and DNA damage—they begin secreting a pro-inflammatory cocktail known as the senescence-associated secretory phenotype, or SASP. This mixture of cytokines, chemokines, and matrix-degrading enzymes accelerates the senescence of neighboring cells, disrupts the vascular barrier, and promotes clot formation. Mechanically, senescent endothelium diminishes the bioavailability of nitric oxide, the molecule responsible for vasorelaxation, leading to vasoconstriction, arterial stiffening, and hypertension. Deciphering the upstream triggers of this transition, the review contends, is paramount for developing effective vascular interventions.

TLR4 is a pattern recognition receptor best known as a sentinel of the innate immune system, binding both external pathogens and internally derived danger signals. Under physiological conditions, endothelial TLR4 acts as a surveillance system that coordinates tissue repair, angiogenesis, and vascular wall reconstruction. When activated by damage-associated molecular patterns, or DAMPs, it induces vascular endothelial growth factor, stimulating endothelial migration and tube formation for wound healing. In the lung, endothelial TLR4 is even essential for oxidative stress defense and tissue homeostasis. But under persistent metabolic stress—prolonged hyperglycemia or exposure to oxidized low-density lipoprotein—this protective architecture shifts into a maladaptive state, and chronic TLR4 hyperactivation begins to fuel the very senescence it evolved to prevent.

The mechanistic details are striking. When persistently stimulated by circulating DAMPs or oscillatory shear stress, endothelial TLR4 activates the NF-κB pathway through MyD88 and TRIF adaptor proteins while simultaneously assembling the NADPH oxidase 2 complex, producing a massive surge of superoxide. This oxidative flood keeps endothelial nitric oxide synthase inactive, drastically reducing local nitric oxide and generating toxic peroxynitrite. The accumulating oxidative stress induces double-stranded DNA breaks, activating the classic DNA damage response: ATM kinase phosphorylates p53, which in turn drives transcription of the cyclin-dependent kinase inhibitors p21 and p16INK4a, forcing cells into irreversible G1-phase arrest. What follows is a vicious, self-amplifying loop—senescent endothelial cells upregulate TLR4 on their own surfaces, secrete SASP factors such as IL-6, IL-1β, and TNF-α, induce bystander senescence in healthy neighbors, and further entrench the pathological state. In experimental settings, senescent endothelial cells display a ninefold upregulation of the adhesion molecule ICAM-1 upon secondary stimulation compared with healthy controls.

Perhaps the review’s most consequential contribution is its catalog of tissue-specific paradoxes. In aging mouse models, TLR4 levels rise in the heart and aorta, accelerating vascular decline, and microvascular endothelial cells—expressing far more of the TLR4 co-receptor CD14 than their macrovascular counterparts—mount an amplified IL-6 cascade that destabilizes atherosclerotic plaques. Yet in the lung, the opposite holds: endothelial TLR4 actively suppresses the senescence gene p16INK4a through HDAC2-mediated histone deacetylation, and its loss precipitates emphysema-like alveolar dilation. In diabetic retinopathy, deleting TLR4 specifically in retinal endothelial cells rescues the blood-retinal barrier, whereas deleting it in adjacent Müller cells does not. In the brain, acute activation of endothelial TLR4 triggers rapid internalization of the tight junction protein claudin-5, collapsing the blood-brain barrier—an effect entirely absent in endothelial-specific knockout mice.

Even more paradoxical is an expression asymmetry between neighboring cell types. Senescent endothelial cells upregulate their own TLR4, driving chronic vascular decline, yet they simultaneously restrict the release of exosomal miR-326-3p, a microRNA that downregulates TLR4 in adjacent skin fibroblasts. The resulting TLR4 deficiency in fibroblasts impairs basal survival signaling and accelerates their aging. The same aging phenotype, in other words, is driven by an excess of TLR4 in one cell type and a deficit in another—a finding that demolishes any notion of the receptor as a simple pro-aging villain.

The clinical record bears out the danger of oversimplification. Epidemiological data suggest that genetically blunted TLR4 signaling protects against vascular aging: in a cohort of 2,679 patients with coronary artery disease, carriers of the loss-of-function variant rs4986790 showed a significantly attenuated rise in systolic blood pressure over time, and an Italian study of 810 subjects found that carriers of the Asp299Gly allele had lower levels of interleukin-6 and fibrinogen and reduced atherosclerosis risk. But large-scale Phase III trials of systemic TLR4 antagonists—the MD-2 blocker eritoran and the intracellular inhibitor TAK-242—failed to reduce mortality in severe sepsis and were terminated early. Complete abrogation of TLR4 signaling dismantles innate immune defense, as TLR4-deficient mice suffer fatal gram-negative pneumonia, and aged knockout mice develop spontaneous obesity driven by skewed immune profiles. Systemic blockade even disrupts dendritic cell maturation and cytotoxic T-cell priming, potentially accelerating tumor growth.

The alternative, the authors argue, is precision senotherapeutics: confining TLR4 modulation strictly to pathologically altered endothelial cells while leaving homeostatic compartments untouched. Pharmacological agents already in clinical use offer a starting point. Heparin suppresses endothelial TLR4 and MyD88 expression in a dose-dependent manner, blocking NF-κB nuclear translocation and reducing SASP components to delay senescence. The Hedgehog pathway agonist SAG rescues placental and uterine artery angiogenesis impaired by TLR4 hyperactivation, while sildenafil and nitrite supplementation bypass TLR4 injury by restoring nitric oxide signaling in neonatal necrotizing enterocolitis. Upstream strategies are equally promising: epigenetic targeting of the Ash2l gene dampens lipid uptake and stabilizes atherosclerotic plaques, RAGE silencing downregulates TLR4 expression in diabetic vasculature, and anti-eNAMPT antibodies preserve endothelial junctional integrity in acute lung injury.

The most futuristic frontier lies in targeted delivery. Nanostructured lipid carriers functionalized with anti-VCAM-1 antibodies selectively accumulate in inflamed atherosclerotic vessels while bypassing healthy ones, and have been used to deliver melatonin that silences the endothelial TLR4/NF-κB cascade and suppresses inflammatory pyroptosis. E-selectin-targeted multistep vectors ferry therapeutic microRNAs such as miR-146a and miR-181b to activated endothelium, shrinking atherosclerotic lesions, while dual-targeting lipid vehicles conjugated with both anti-VCAM-1 and anti-E-selectin antibodies achieve complete gene silencing in activated endothelial cells with no detectable systemic toxicity. Even plant-derived exosomes are entering the arena: V-Onex, engineered by grafting a VCAM-1-binding peptide onto onion-derived extracellular vesicles, homes selectively to atherosclerotic endothelial layers. Aptamer-drug conjugates that unlock only in the presence of elevated lysosomal β-galactosidase promise to release senolytic payloads exclusively inside senescent cells.

Significant hurdles remain before these platforms reach the clinic. Exosomes offer high biocompatibility but suffer from mass-production and purification challenges and risk rapid clearance in vivo; synthetic nanoparticles allow precise structural tuning but face scalability constraints and unresolved questions about long-term biodistribution and toxicity. Hybrid technologies fusing the two approaches are being proposed as a compromise. Still, the conceptual shift articulated in this review is clear: vascular aging is driven not by the mere presence of TLR4 signaling but by its localized hyperactivation and dysregulated ligand-receptor kinetics. The next generation of cardiovascular and anti-aging therapies, the authors conclude, must move past simple receptor blockade toward spatiotemporally targeted restoration—treating the endothelium not as a uniform sheet of tissue, but as a mosaic of specialized niches, each demanding its own precisely calibrated molecular rheostat.

Subject of Research: The role of endothelial Toll-like receptor 4 signaling in vascular senescence and the development of targeted senotherapeutic strategies

Article Title: Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics

Article References: Kim, H.-J., Lee, J.-H., & Hwangbo, C. (2026). Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics. Aging Cell, 25(10), Article e70757. https://doi.org/10.1111/acel.70757

Image Credits: AI Generated

DOI: 10.1111/acel.70757

Keywords: TLR4, endothelial senescence, vascular aging, SASP, senotherapeutics, senolytics, senomorphics, nanoparticle drug delivery, NF-kB, nitric oxide, atherosclerosis, targeted therapy

Cancer-associated fibroblasts, or CAFs, are the most abundant stromal cells in many solid tumors, including cervical cancer. Far from being passive scaffolding, they are dynamic, plastic cells that actively shape the tumor microenvironment. The review, led by Jingyang Lan, Chengming Tian, Tong Wang, and colleagues at Shengjing Hospital of China Medical University, emphasizes that CAFs in cervical cancer display remarkable heterogeneity. They can adopt myofibroblastic states marked by alpha-smooth muscle actin and contractile extracellular matrix deposition, inflammatory states driven by interleukin-6 and other cytokines, or antigen-presenting states that express major histocompatibility complex class II molecules. Each of these states exerts different effects on tumor growth, immune surveillance, and treatment response, which is precisely what makes identifying therapy-induced changes among them so technically difficult.

The central concept the authors develop is the therapy-induced senescent cancer-associated fibroblast, abbreviated sCAF. Cellular senescence is a state of stable growth arrest: the cell remains alive and metabolically active but can no longer divide. It is typically triggered by DNA damage, oxidative stress, or oncogenic signaling, and it is enforced by pathways involving p53, p21, and p16. Radiotherapy and chemoradiotherapy are potent inducers of DNA damage, and while the clinical goal is to push tumor cells past the point of repair into lethal damage, stromal cells caught in the blast zone may instead arrest in this senescence-like state. The result is a population of fibroblasts that survive treatment, stop proliferating, but do not die—and, crucially, do not fall silent.

What makes senescent cells biologically potent is their secretory behavior. Senescent CAFs develop what researchers call the senescence-associated secretory phenotype, or SASP: a sustained release of inflammatory cytokines such as interleukin-6 and interleukin-1 beta, chemokines including CXCL12 and interleukin-8, growth factors such as insulin-like growth factor 1, and matrix-remodeling enzymes like matrix metalloproteinases. This secretome is not a passive byproduct; it is an active signaling network. In the post-treatment tumor bed, where residual cancer cells are struggling to survive amid hypoxia, nutrient deprivation, and immune attack, SASP factors can provide exactly the survival signals those cells need—promoting proliferation of surviving clones, epithelial-to-mesenchymal transition, stem-like properties, and resistance to further therapy.

The review lays out several mechanistic channels through which putative sCAFs could undermine chemoradiotherapy outcomes. Beyond SASP signaling, senescent fibroblasts reorganize the extracellular matrix, depositing collagen and other structural proteins in ways that stiffen tissue, alter mechanical signaling through pathways such as YAP/TAZ and focal adhesion kinase, and physically impede drug penetration and immune cell infiltration. They also engage in metabolic crosstalk: senescent cells are known to alter glucose and lactate handling, and the review highlights markers such as glucose transporter 1 and lactate dehydrogenase in this context, suggesting that sCAFs could rewire nutrient availability in the treated microenvironment to favor residual tumor cells. Finally, they modulate immunity, recruiting regulatory T cells and myeloid-derived suppressor cells while dampening cytotoxic CD8-positive T cell activity, effectively building an immunosuppressive shield around surviving cancer cells.

Identifying these cells unambiguously is harder than it sounds, and the authors are notably careful on this point. Common senescence markers—senescence-associated beta-galactosidase activity, phosphorylated histone H2AX as a readout of DNA damage, p16 and p21 expression—are neither perfectly specific nor universally expressed. Fibroblast markers themselves, such as fibroblast activation protein, platelet-derived growth factor receptor alpha and beta, and type I collagen, vary across CAF states. A single marker is therefore insufficient. The review argues for composite criteria that combine senescence readouts, fibroblast lineage markers, functional signatures such as SASP expression, and spatial information from multiplex imaging of post-treatment tissue. Equally important, the authors frame sCAFs not as a discrete lineage but as heterogeneous, stress-adapted states that CAFs can enter and potentially exit—a conceptual shift with real consequences for how biomarker studies should be designed.

The authors also draw a disciplined line between direct evidence from cervical cancer and mechanistic extrapolation from other tumor types. Much of what is known about therapy-induced senescence in stromal cells comes from breast, pancreatic, and lung cancer models, where irradiated or chemotherapy-exposed fibroblasts have been shown to promote tumor cell survival and invasion through SASP-mediated signaling. Cervical cancer-specific data are still limited, and human papillomavirus oncogene signaling adds a layer of complexity unique to this disease. By explicitly separating what has been demonstrated in cervical tissue from what is inferred across tumors, the review provides an honest map of where the field stands—and where the evidentiary gaps lie.

The therapeutic implications are nonetheless tantalizing. Senolytic drugs, which selectively eliminate senescent cells by disabling their anti-apoptotic survival pathways, have already shown promise in preclinical and early clinical settings outside oncology; agents such as the FOXO4 D-retro-inverso peptide and combinations targeting heat shock protein 90 or BCL-2 family proteins are being explored. Applied after chemoradiotherapy, senolytics could in principle clear sCAFs from the treated tumor bed before they can nurture residual disease. Senomorphics, by contrast, do not kill senescent cells but suppress their secretory output, for example by dampening NF-kappa-B, JAK-STAT, or PI3K-AKT signaling, thereby muting the SASP without removing the cells. A third strategy is stromal reprogramming—pushing senescent or pro-tumor CAFs back toward a quiescent or tumor-suppressive phenotype—while metabolic interventions could cut off the nutrient crosstalk between sCAFs and cancer cells.

Targeted drug delivery adds another layer of opportunity. Fibroblast activation protein inhibitors, originally developed as imaging and therapeutic agents for CAF-rich tumors, could be adapted to deliver cytotoxic or senolytic payloads specifically to activated stromal cells, sparing normal tissue. The review also notes the potential of fibroblast activation protein-targeted positron emission tomography imaging, a technology already in clinical use at centers including the authors’ own nuclear medicine department, to noninvasively map CAF burden before and after treatment. If sCAF abundance or distribution proves predictive of recurrence, such imaging could become a biomarker-guided tool for deciding which patients need stromal-targeted consolidation therapy after chemoradiotherapy.

Timing, the authors stress, will be everything. Senescence is a double-edged sword: in some contexts, therapy-induced senescence in tumor cells is a desirable outcome that halts proliferation and can even alert the immune system, and premature clearance of senescent stromal cells during active treatment might theoretically undermine wound healing or anti-tumor immunity. Integrating senolytic or senomorphic interventions safely with concurrent chemoradiotherapy will require knowing when sCAFs appear, how long they persist, and which subpopulations actually drive resistance. Establishing that clinical relevance—through longitudinal sampling, spatial profiling of post-treatment specimens, and biomarker-driven trials—is the review’s central call to action. If the framework holds up, the era of treating only the cancer cell may give way to a more sophisticated approach: managing the entire, therapy-scarred ecosystem that a tumor leaves behind.

Subject of Research: Therapy-induced senescent cancer-associated fibroblasts and treatment resistance in cervical cancer

Article Title: Therapy-induced senescent cancer-associated fibroblasts in cervical cancer: Mechanisms of treatment resistance and therapeutic opportunities

Article References: Lan, J., Tian, C., Wang, T., Yu, Y., Guo, Y., Shi, J., Xu, C., & Sun, H. (2026). Therapy-induced senescent cancer-associated fibroblasts in cervical cancer: Mechanisms of treatment resistance and therapeutic opportunities. BMC Medicine. https://doi.org/10.1186/s12916-026-05268-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05268-y

Keywords: cervical cancer, cancer-associated fibroblasts, cellular senescence, chemoradiotherapy, tumor microenvironment, SASP, treatment resistance, senolytics, senomorphics, extracellular matrix, cancer immunosuppression, BMC Medicine

The SASP is a staggeringly complex output. Senescent cells release pro-inflammatory cytokines such as IL-6, IL-8, TNF-α, and IL-1 family members; chemokines including CCL2, CCL5, and a host of CXCL proteins; growth factors such as VEGF, TGF-β, and HGF; matrix-degrading enzymes like MMP-2 and MMP-9; extracellular matrix fragments; and extracellular vesicles carrying microRNAs and proteins. The precise recipe depends on the cell’s origin, the trigger that induced senescence, and the local microenvironment, which helps explain why senescence can look heroically protective in one setting and dangerously corrosive in another. What is clear is that these secreted factors act both locally and systemically, allowing a relatively small population of arrested cells to exert outsized influence over the tumor microenvironment.

Timing turns out to be decisive. Experimental evidence indicates that an early SASP phase emerges within roughly two to four days after senescence induction, shaped by NOTCH-dependent signaling and enriched in TGF-β family members and matrix-remodeling proteins. By about seven to ten days, a more aggressive inflammatory program dominated by NF-κB-driven cytokines and chemokines takes over. In acute, transient phases, the SASP can function as a biological alarm bell: it recruits natural killer cells, cytotoxic CD8-positive T cells, macrophages, and dendritic cells that clear damaged or pre-malignant cells, and it can impose paracrine senescence on neighbors, forcing them into the same growth-arrested state. Preclinical liver and pancreatic cancer models show that this senescence surveillance genuinely suppresses tumor formation.

When senescence persists, however, the story darkens. Therapy-induced senescence, produced by genotoxic chemotherapy, radiation, and targeted drugs, leaves senescent cells lodged in tissues for months or years, chronically secreting inflammatory mediators. Studies estimate that markers of senescence appear in 31 to 66 percent of tumors after chemotherapy, and senescent cells also accumulate in surrounding healthy tissue. The resulting chronic SASP promotes extracellular matrix remodeling, neoangiogenesis, immune suppression, and cancer cell plasticity. In breast cancer models, IL-6 and IL-8 drive epithelial-mesenchymal transition, mammosphere formation, and stem-like phenotypes marked by CD44 and ALDH1. Senescent fibroblasts co-cultured with cancer cells enhance invasion, while residual tumor cells exposed to therapy-induced SASP develop measurable resistance to doxorubicin, cisplatin, and radiation.

Underneath this behavior lies an intricate regulatory network. Persistent DNA damage response signaling through ATM and ATR initiates the program, while the cGAS-STING pathway detects cytoplasmic chromatin fragments leaking from an unstable genome and triggers type I interferon responses. NF-κB acts as a transcriptional amplifier of inflammatory genes, NOTCH tunes the composition of the secretome between inflammatory and matrix-remodeling states, mTOR controls translational output, and JAK/STAT signaling sustains the whole circuit through IL-6-driven feed-forward loops. Crucially, no single pathway is sufficient to induce a full SASP on its own, which explains why the phenotype varies so dramatically across tumor types, senescence triggers, and patients—and why targeting it clinically is so challenging.

The immune consequences are especially consequential for modern oncology. Depending on context, the SASP can either enhance or sabotage immunotherapy. Acute senescence induced by CDK4/6 inhibitors in melanoma models produces a chemokine-rich secretome that draws dense infiltrates of CD4-positive and CD8-positive T cells, and interferon signaling triggered by such drugs improves antigen presentation and responsiveness to checkpoint blockade. Conversely, chronic SASP recruits myeloid-derived suppressor cells and regulatory T cells through CCL2, IL-1β, IL-6, and CSF-1, blunting the cytotoxic T-cell activity that immune checkpoint inhibitors depend upon. Senescent stromal cells in the breast, pancreas, and liver secrete VEGF, PDGF, and FGF family members that stimulate tumor vasculature, while senescent cancer-associated fibroblasts stiffen the extracellular matrix, activating mechanotransduction pathways that push tumors toward invasion and metastasis.

Therapeutically, researchers are pursuing two complementary strategies. Senolytics aim to kill senescent cells outright by exploiting the anti-apoptotic machinery—BCL-2 family signaling, PI3K/AKT, and FOXO4-p53 interactions—that keeps them alive. Navitoclax (ABT-263) has shown preclinical activity across ovarian, breast, lung, pancreatic, and blood cancers, though thrombocytopenia limits its clinical use. The dasatinib-plus-quercetin combination, the flavonoid fisetin, the FOXO4-DRI peptide, and procyanidin C1 broaden the arsenal, and novel drug-delivery systems such as galacto-oligosaccharide encapsulation are being engineered to reduce systemic toxicity. Senomorphics, by contrast, reshape the SASP without killing the cell: rapamycin suppresses SASP translation through mTOR, JAK inhibitors such as ruxolitinib blunt IL-6 and IL-8 signaling, and biologics including anakinra, siltuximab, and tocilizumab neutralize specific cytokines. Natural polyphenols like curcumin, apigenin, and resveratrol show senomorphic activity in preclinical systems by inhibiting NF-κB and mTOR pathways.

Timing, once again, complicates everything. Administered too early, senolytics or SASP suppression could destroy beneficial transient senescence that recruits immune clearance of damaged cells; administered too late, senomorphics may merely slow an already entrenched pro-tumor inflammatory state. Preclinical lymphoma models demonstrate that blocking NF-κB-dependent SASP during chemotherapy actually diminishes treatment benefit by preventing NK-cell recruitment, while ablating radiation-senescent cells in the brain microenvironment reduces glioblastoma recurrence. These opposing results underscore that senescence-targeted interventions must be sequenced carefully relative to the primary therapy, tuned to tumor type, and calibrated to the senescence burden carried by each patient—a burden that rises sharply with age and obesity, both of which amplify pro-tumorigenic SASP signaling.

Translating these insights into the clinic will also require better biomarkers. SASP components such as IL-6 and IL-8 overlap heavily with inflammatory molecules produced by immune and epithelial cells during infection or injury, so single-cytokine measurements are unreliable. Emerging single-cell and spatial multi-omics technologies, together with computational resources like the SASP Atlas, now allow researchers to map distinct senescent cell states—inflammatory, fibrotic, metabolic, and immune-modulatory—within intact tumors, and multi-marker panels combining secreted factors with p16, p21, and DNA damage markers are being validated for monitoring therapy response. For now, the review’s authors conclude, senolytics and senomorphics should be regarded as investigational rather than established cancer treatments. Yet the underlying message is unambiguous: the same biological program that once looked like a simple off switch for cancer may prove to be one of oncology’s most powerful and nuanced therapeutic levers, provided clinicians learn precisely when to silence it, when to exploit it, and when to eliminate it altogether.

Subject of Research: Senescence-associated secretory phenotype remodeling of the tumor microenvironment and its implications for cancer progression and senotherapeutic treatment strategies

Article Title: A Review of Senescence‐Associated Secretory Phenotype‐Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy

Article References: Pallatt, S., Nambidi, S., Banerjee, A., & Pathak, S. (2026). A Review of Senescence‐Associated Secretory Phenotype‐Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy. Cancer Reports, 9(9), Article e70682. https://doi.org/10.1002/cnr2.70682

Image Credits: AI Generated

DOI: 10.1002/cnr2.70682

Keywords: cellular senescence, SASP, tumor microenvironment, senolytics, senomorphics, therapy-induced senescence, cancer immunotherapy, IL-6, extracellular matrix remodeling, cancer-associated fibroblasts, biomarkers, drug resistance

The central actor in this story is the senescence-associated secretory phenotype, or SASP. Senescent cells are not simply dormant; they secrete a cocktail of pro-inflammatory cytokines, chemokines, matrix metalloproteinases and growth factors. In the ageing bone microenvironment, this secretion comes from a surprising range of cell types. Senescent osteocytes, the mechanosensing cells entombed in mineralised matrix, senescent mesenchymal stem cells that would otherwise generate new osteoblasts, senescent osteoblasts themselves, immune cells resident in the marrow, and vascular endothelial cells lining the bone’s rich blood supply all contribute to the SASP. The result is a persistent, locally generated inflammatory input that remoulds skeletal biology from within.

What makes the review’s argument distinctive is its claim about convergence. The SASP is not a separate pathway running in parallel to the classical causes of osteoporosis. Instead, the factors released by senescent cells feed directly into the same signalling axes that estrogen deficiency, glucocorticoid excess and mechanical unloading exploit. These include the RANKL/OPG axis, which governs osteoclast formation and bone resorption; the Wnt/β-catenin pathway, which drives osteoblast differentiation and bone formation; and the NF-κB signalling network, the master regulator of inflammation. By flowing into these well-characterised channels, senescence amplifies resorption while suppressing formation, adding an accelerating force to mechanisms clinicians already recognise.

The molecular detail is striking. SASP cytokines such as interleukin-6, working through its soluble receptor, can potentiate RANKL-induced osteoclast differentiation via NF-κB, ERK and JNK signalling. Chemokines like CCL2 recruit inflammatory cells into the marrow, while CCL3 has been shown to cause bone loss and marrow adiposity in aged mice. SASP components also include Wnt antagonists such as sclerostin, which binds the LRP5/6 co-receptors and blocks the canonical Wnt signal that osteoblasts need to build bone. Sclerostin additionally stimulates osteocyte support of osteoclast activity through a RANKL-dependent pathway, meaning a single SASP constituent can simultaneously dampen formation and promote resorption. Osteocytes, long appreciated as endocrine cells and master orchestrators of remodelling, sit at the centre of this regulatory web, expressing RANKL and controlling both sides of the remodelling cycle.

The regulation of the SASP itself is equally intricate. NF-κB not only mediates the downstream effects of SASP factors but also drives the secretory programme within senescent cells. The inflammasome coordinates paracrine senescence, allowing senescent cells to spread their state to healthy neighbours. mTOR signalling promotes the translation of interleukin-1 alpha, a keystone of the pro-tumorigenic SASP, while p38 MAPK regulates the phenotype independently of the canonical DNA damage response. More recently, cGAS-STING signalling, triggered by leaking DNA in senescent cells, has emerged as an amplifier of the ageing process through remodelling of immune function. Epigenetic changes add another layer of control, and extracellular vesicles, tiny membrane-bound packages, have been identified as key carriers that ferry SASP cargo between cells, spreading senescence paracrinally through the marrow and beyond.

Different skeletal cell types contribute distinct SASP profiles. In osteoprogenitors expressing the transcription factor Osx1, DNA damage and senescence deplete the pool of cells available to form bone with age. Senescent mesenchymal stromal cells shift toward adipogenesis, contributing to the fatty marrow that accumulates with ageing and obesity and further impairing both blood cell and bone regeneration. Osteocyte senescence has been documented in type 2 diabetes, where accelerated senescence of these matrix-embedded cells is associated with skeletal fragility, and radiation has been shown to induce a primary osteocyte senescence phenotype that alters mesenchymal stem cell differentiation through paracrine signalling. Senescent osteocytes also undergo biophysical stiffening, potentially compromising their mechanosensing function. Even osteoclasts display a protective role in this landscape, shielding bone blood vessels from senescence through the angiogenin/plexin-B2 axis, a reminder that the senescence story is not uniformly destructive.

The review carefully distinguishes how senescence participates in age-related, postmenopausal and secondary osteoporosis. In natural ageing, senescent cell burden accumulates gradually and contributes to the slow deterioration of bone mass and microarchitecture, including de novo intracortical remodelling and porosity. In postmenopausal osteoporosis, estrogen deficiency and senescence operate as partly independent inputs; studies in young adult mice and older humans indicate that neither fully explains the other, yet both converge on the same oxidative stress and NF-κB-dependent mechanisms. In secondary forms, the evidence is particularly vivid. Glucocorticoid-induced bone loss can be prevented in mice by targeting cellular senescence through modulation of the DPP4-GLP-1 axis. Radiation-induced osteoporosis is driven specifically by p21-positive, rather than p16-positive, senescent cells, and clearing p21-high cells prevents both bone loss and marrow adiposity. Chemotherapy drives senescence in adipo-lineage cells that then promote bone loss, although one 2025 study found senolytics did not prevent chemotherapy’s adverse skeletal effects, underscoring that the picture remains nuanced.

It is the therapeutic implications that give the review its urgency. When senescent cells were cleared in aged mice, either genetically or pharmacologically, age-related bone loss was prevented, providing proof of concept that the SASP is a distinct and independently addressable contributor to skeletal ageing. Senolytic drugs such as the dasatinib and quercetin combination, discovered by exploiting the survival dependencies of senescent cells, have since shown benefit in multiple preclinical models, including postmenopausal, glucocorticoid-induced, diabetic, hypoxia-associated and vitamin D insufficiency-related bone loss. Intermittent senolytic treatment has also been reported to improve responsiveness to mechanical loading in the skeletons of aged mice, linking senescence clearance to the well-known anabolic effects of exercise. A phase 2 randomised controlled trial has now tested intermittent senolytic therapy on bone metabolism in postmenopausal women, marking a critical step toward clinical translation.

Delivery remains a central challenge, and the field is responding with engineering ingenuity. Bone-targeted nanoparticles and nanomaterials are being developed to concentrate senolytics and other therapeutics in the skeleton, and liposomal senolytic formulations have alleviated senescence-induced bone loss in preclinical work. Apoptotic vesicle-mediated senolytic approaches have been shown to require mechanical loading, suggesting that drug therapy and physical activity may need to be combined. Alternative senomorphic strategies aim not to kill senescent cells but to quiet their secretions. JAK inhibition has been shown to alleviate the SASP and frailty in old age, rapamycin extends lifespan in mice partly through mTOR modulation, and glutaminolysis inhibition achieves senolysis through metabolic vulnerability. Rejuvenating senescent bone marrow stromal cells by enhancing TFEB-mediated autophagy has alleviated age-related bone loss in middle-aged mice, and metformin’s effects on bone metabolism are under active investigation.

The authors are candid about the gaps. Senolytics and senomorphics must be evaluated against established osteoporosis treatments, from bisphosphonates and denosumab to the anabolic agents teriparatide and romosozumab, which themselves reshape the RANKL/OPG and Wnt pathways. Denosumab discontinuation causes rebound bone turnover that requires careful sequencing strategies, and the same scrutiny of long-term skeletal outcomes must be applied to senescence-targeted approaches. Biomarker validation is a priority: proteomic atlases of senescence-associated secretomes are enabling the development of circulating biomarkers, and emerging techniques such as spatial transcriptomics are mapping where senescent cells reside within bone tissue. The review also highlights that p16-positive and p21-positive cells represent distinct senotypes with different functional consequences, meaning precision may matter when targeting them. As the population ages and osteoporosis imposes an ever-heavier burden of fragility fractures, the convergence of senescence biology with classical skeletal physiology offers a genuinely new therapeutic frontier, one where ridding bone of its zombie cells, or silencing their inflammatory chorus, could preserve skeletal strength deep into old age.

Subject of Research: Cellular senescence and the senescence-associated secretory phenotype in skeletal ageing and osteoporosis

Article Title: Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis

Article References: Liu, H., & Lei, B. (2026). Cellular senescence and the SASP in skeletal ageing: convergent mechanisms of progressive bone loss in osteoporosis. Biogerontology, 27(5), Article 164. https://doi.org/10.1007/s10522-026-10508-y

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10508-y

Keywords: cellular senescence, SASP, osteoporosis, skeletal ageing, senolytics, senomorphics, osteocytes, inflammaging, RANKL/OPG, Wnt signalling, bone remodeling, senescence biomarkers

The central claim of the article, titled Metabolism licenses the senescence secretome, is that metabolic state functions as a gatekeeper determining which inflammatory and growth-promoting signals a senescent cell actually produces. In other words, two cells can be equally senescent by the classical criteria, showing stalled cell cycles, enlarged morphology and markers such as senescence-associated beta-galactosidase, yet produce dramatically different secretomes depending on how their metabolic machinery is configured. This reframing has significant consequences, because it suggests that targeting metabolism could offer a way to silence the harmful secretions of senescent cells without necessarily eliminating the cells themselves.

To understand why this idea matters, it helps to review what the senescence secretome actually contains. Depending on the cell type and the trigger, senescent cells can secrete pro-inflammatory cytokines such as interleukin-6 and interleukin-8, chemokines that recruit immune cells, matrix-remodeling enzymes including matrix metalloproteinases, growth factors that can drive neighboring cells to proliferate, and a variety of lipid mediators and extracellular vesicles carrying proteins and nucleic acids. In the short term, this signaling can be beneficial. It alerts the immune system to a potentially dangerous cell, promotes wound healing and contributes to tissue repair after injury. The problems arise when senescent cells accumulate with age or in diseased tissue, because their chronic secretory output then becomes a persistent source of low-grade inflammation, a phenomenon often described as inflammaging.

The traditional view of how the secretome is controlled has centered on DNA damage signaling. When cells experience telomere shortening, oxidative stress, oncogene activation or genotoxic drugs, they activate pathways involving the ATM and ATR kinases, which in turn engage the p53 and p21 axis and the p16INK4a and retinoblastoma pathway. These cascades enforce the cell-cycle arrest, and through the transcription factors NF-kappaB and C/EBP beta they also drive expression of many secreted factors. This DNA damage-centered model explains a great deal, but it leaves an important observation unexplained: the secretome varies enormously between contexts, and the same senescence trigger can produce very different inflammatory outputs in different metabolic environments.

The Cell Research perspective proposes that metabolism supplies the missing layer of regulation. Senescent cells undergo profound metabolic rewiring. They frequently display increased glycolysis, elevated mitochondrial oxidative phosphorylation, altered autophagic flux, changes in lipid metabolism and, in many cases, a shift toward biosynthetic programs that support their survival despite being unable to divide. Mitochondrial dysfunction is a particularly well-documented feature, and mitochondria that lose their integrity can release mitochondrial DNA and other damage-associated molecular patterns that amplify inflammatory signaling through innate immune sensors such as cGAS and Toll-like receptors. In this way, the metabolic state of the cell directly feeds the signaling circuits that assemble the secretome.

Several specific metabolic nodes illustrate the principle. The mevalonate pathway, best known for producing cholesterol, also generates isoprenoid intermediates required for the prenylation of small GTPases, and inhibition of this pathway with statins has been shown in multiple studies to blunt the secretion of inflammatory cytokines by senescent cells. Prostaglandin metabolism is another critical branch: the enzyme COX-2 and its downstream prostaglandin E2 production have been linked to the maintenance of the senescence program itself, and interfering with prostaglandin signaling can weaken both senescence and its secretory output. NAD metabolism, sirtuin activity, acetyl-CoA availability and histone acetylation states all influence how accessible the genes encoding secreted factors are to the transcriptional machinery. Even the availability of glucose and amino acids can shift the balance between a restrained and a fully inflammatory secretory phenotype.

This metabolic licensing concept also helps explain one of the most puzzling features of senescence biology: its heterogeneity. Single-cell analyses have revealed that senescent cells in the same tissue can express strikingly different sets of secreted factors, and that this diversity changes with age, tissue type and disease context. If the secretome were determined solely by the DNA damage response, one might expect more uniformity. But if the secretome is licensed by metabolism, then the local nutrient environment, oxygen tension, mitochondrial health and lipid availability of each cell would naturally produce a spectrum of secretory states. This heterogeneity is not noise; it is a direct readout of each cell’s metabolic circumstances, and it may explain why senescent cells can be reparative in one setting and destructive in another.

The therapeutic implications are considerable. Over the past decade, a class of drugs called senolytics has been developed to selectively kill senescent cells, and early clinical trials have reported encouraging results in conditions ranging from idiopathic pulmonary fibrosis to diabetic kidney disease. But clearing senescent cells entirely may not always be desirable, given their documented roles in wound healing, tissue regeneration and tumor suppression. An alternative strategy, sometimes called senomorphics, aims to reprogram senescent cells so that they retain their growth arrest and tumor-suppressive functions while losing their inflammatory secretions. The metabolic licensing framework provides a conceptual foundation for this approach: if metabolism licenses the secretome, then metabolic interventions, whether through statins, NAD-boosting compounds, mitochondrial modulators or dietary strategies, could in principle dial down the harmful components of the secretome while leaving the protective aspects of senescence intact.

The perspective also raises important questions for future research. Which metabolic enzymes are the critical licensing factors in vivo, and do they differ between tissues? How reversible is metabolic licensing, and can a senescent cell whose secretome has been silenced by metabolic intervention be pushed back into a benign state permanently, or only transiently? How do systemic factors such as diet, exercise and obesity, all of which reshape whole-body metabolism, modulate the secretory behavior of the senescent cells distributed throughout our tissues? And how do the metabolic states of senescent cells interact with the immune system, which must constantly decide whether to clear, tolerate or be activated by these cells? Answering these questions will require integrating metabolomics, single-cell transcriptomics and functional assays in physiologically relevant models, an effort the authors argue should now be a priority for the field.

What emerges from this analysis is a view of the senescent cell as a metabolically governed signaling hub rather than a passive casualty of damage. The DNA damage response may initiate senescence, but metabolism determines the character and intensity of the message the cell broadcasts to its neighbors. As the global population ages and age-related diseases place growing demands on health systems, the ability to modulate, rather than merely eliminate, senescent cells could become a cornerstone of geriatric medicine. The idea that metabolism licenses the senescence secretome offers both a unifying explanation for the heterogeneity that has long frustrated researchers and a practical roadmap for interventions that could preserve the benefits of cellular senescence while curbing its inflammatory costs. It is a reminder that in biology, as in economics, what a cell says depends heavily on the resources it has to spend.

Subject of Research: Metabolic regulation of the senescence-associated secretory phenotype in aging and disease

Article Title: Metabolism licenses the senescence secretome

Article References: Picallos Rabina, P., & Demaria, M. (2026). Metabolism licenses the senescence secretome. Cell Research. https://doi.org/10.1038/s41422-026-01295-9

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01295-9

Keywords: cellular senescence, senescence secretome, metabolism, inflammaging, mitochondrial dysfunction, senolytics, senomorphics, DNA damage response, aging, cytokines, NAD metabolism, Cell Research